-
Oxaliplatin Boosts Survival in Stage III CRC Only Up to 70 Years, Study Finds
07 Aug 2025 04:11 GMT
… more likely to discontinue treatment.
Oxaliplatin use in older adults with … uncertain. Although some pooled trial analyses suggest survival benefits regardless … researchers evaluated the association between oxaliplatin use and chemotherapy discontinuation …
-
Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy
06 Aug 2025 18:02 GMT
… of melanoma. Front Bioeng Biotechnol. 2023;11:1294074. … methotrexate, and oxaliplatin.130 This class of medications can induce … Furthermore, during clinical trials, potential adverse host … photodynamic therapy in melanoma treatment. Pharmaceutics. 2023;15(8): …
-
When do you know when it’s time to stop cancer treatment? She knew – her final act of control
04 Aug 2025 10:19 GMT
… blamed on paclitaxel or oxaliplatin were just as much … dear friend go from treatment to treatment to treatment. Never, quote, “ … patients in the trial responded to that drug alone without the … 1992 examination of the doctor-patient relationship they’d …
-
July's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements
01 Aug 2025 15:02 GMT
… gemcitabine and oxaliplatin, indicating that … pivotal IGNYTE trial (NCT03767348) … Treatment: ICT01 Receives FDA Orphan Drug Designation
On July 18, the FDA granted orphan drug … treatment of early relapsed/refractory multiple myeloma.
FDA Greenlights Trials …
-
Dr Sinicrope on the Clinical Implications of the ATOMIC Trial for Stage III dMMR CRC
01 Aug 2025 09:35 GMT
… Meeting, results from the trial demonstrated a statistically significant … to standard adjuvant mFOLFOX6 (modified oxaliplatin, leucovorin, and fluorouracil) chemotherapy … for potential inclusion in future treatment recommendations. With updated guidance, …
-
Onvansertib Shows Promising Early Efficacy in First-Line KRAS-Mutated mCRC
06 Aug 2025 11:23 GMT
… population with limited treatment options. The trial is a … Roger Sidhu, MD, chief medical officer of Cardiff Oncology, … practice-changing phase 3 trials, and demonstrates that … disease, disease progression following oxaliplatin/fluoropyrimidine-based …
-
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
06 Aug 2025 20:15 GMT
… ANAB), a clinical-stage biotechnology company focused on delivering … 2 trial of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin … Phase 2b trial for the treatment of rheumatoid arthritis … payments from the Vanda Pharmaceuticals license agreement; the …
-
OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology
06 Aug 2025 19:07 GMT
… INAVO120 trial (NCT04191499). Findings published in the New England Journal of Medicine … Pharmaceuticals receives European Commission marketing authorization for Ziihera (zanidatamab) for the treatment …
-
Development and Cross-Institutional Validation of a Comprehensive Machine Learning Model Predicting Response to Neoadjuvant Therapy for Rectal Cancer
06 Aug 2025 09:15 GMT
… assist doctors in formulating personalized treatment strategies. … medical records including clinical characteristics, pre-treatment CT, pre-treatment … meta-analysis: oxaliplatin in neoadjuvant treatment for rectal … randomised Phase 3 trial. Lancet Oncol. …
-
Neoadjuvant vs Adjuvant Immunotherapy in Colon Cancer
06 Aug 2025 05:32 GMT
… with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy, providing … results of this trial were presented at the … immunotherapy to standard chemotherapy treatment, improving outcomes for … Holdings AG, Ventana Medical Systems, and Woven Health …